WO2006012507A3 - Methods and compositions for risk stratification - Google Patents

Methods and compositions for risk stratification Download PDF

Info

Publication number
WO2006012507A3
WO2006012507A3 PCT/US2005/026026 US2005026026W WO2006012507A3 WO 2006012507 A3 WO2006012507 A3 WO 2006012507A3 US 2005026026 W US2005026026 W US 2005026026W WO 2006012507 A3 WO2006012507 A3 WO 2006012507A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
approach
cellular
compositions
methods
Prior art date
Application number
PCT/US2005/026026
Other languages
French (fr)
Other versions
WO2006012507A2 (en
Inventor
Omar D Perez
Garry P Nolan
Jonathan M Irish
Original Assignee
Univ Leland Stanford Junior
Omar D Perez
Garry P Nolan
Jonathan M Irish
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Omar D Perez, Garry P Nolan, Jonathan M Irish filed Critical Univ Leland Stanford Junior
Priority to CN200580031373.4A priority Critical patent/CN101023353B/en
Priority to EP05775258A priority patent/EP1771728A2/en
Priority to JP2007522799A priority patent/JP2008507286A/en
Publication of WO2006012507A2 publication Critical patent/WO2006012507A2/en
Publication of WO2006012507A3 publication Critical patent/WO2006012507A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/13—Tracers or tags
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
PCT/US2005/026026 2004-07-21 2005-07-21 Methods and compositions for risk stratification WO2006012507A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN200580031373.4A CN101023353B (en) 2004-07-21 2005-07-21 The method secondary by risk stratification and composition
EP05775258A EP1771728A2 (en) 2004-07-21 2005-07-21 Methods and compositions for risk stratification
JP2007522799A JP2008507286A (en) 2004-07-21 2005-07-21 Methods and compositions for risk stratification

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/898,734 US7393656B2 (en) 2001-07-10 2004-07-21 Methods and compositions for risk stratification
US10/898,734 2004-07-21

Publications (2)

Publication Number Publication Date
WO2006012507A2 WO2006012507A2 (en) 2006-02-02
WO2006012507A3 true WO2006012507A3 (en) 2006-10-12

Family

ID=35613688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026026 WO2006012507A2 (en) 2004-07-21 2005-07-21 Methods and compositions for risk stratification

Country Status (5)

Country Link
US (10) US7393656B2 (en)
EP (2) EP1771728A2 (en)
JP (3) JP2008507286A (en)
CN (1) CN101023353B (en)
WO (1) WO2006012507A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8273544B2 (en) 2008-07-10 2012-09-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8309306B2 (en) 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US8815527B2 (en) 2001-07-10 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US8865420B2 (en) 2004-07-21 2014-10-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US9034257B2 (en) 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US9115384B2 (en) 2001-07-10 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US9182385B2 (en) 2007-08-21 2015-11-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228703A1 (en) * 2002-04-05 2003-12-11 The Regents Of The University Of Michigan Fluorescence resonance energy transfer quantitation and stoichiometry in living cells
WO2005120571A2 (en) * 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
US20060141549A1 (en) * 2004-08-03 2006-06-29 Sudipta Mahajan Cell-based kinase assay
US20080069772A1 (en) * 2004-08-26 2008-03-20 Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum Treatment of transformed or infected biological cells
EP1634603A1 (en) * 2004-08-26 2006-03-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Treatment of transformed or infected biologic Cells
EP1842147A2 (en) * 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Method for modeling cell signaling systems by means of bayesian networks
US20130210034A1 (en) * 2005-11-04 2013-08-15 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
WO2007117423A2 (en) * 2006-03-31 2007-10-18 Cira Discovery Sciences, Inc. Method and apparatus for representing multidimensional data
TWI443063B (en) * 2007-07-11 2014-07-01 Mitsubishi Gas Chemical Co Method for producing regenerative catalyst for producing hydrogen peroxide working solution
GB2455204B (en) * 2007-11-28 2010-07-14 Smart Tube Inc Devices, systems and methods for the collection, stimulation, stabilization and analysis of a biological sample
GB2474146B (en) * 2008-04-29 2013-04-10 Nodality Inc Methods of determining the health status of an individual
US20090269800A1 (en) * 2008-04-29 2009-10-29 Todd Covey Device and method for processing cell samples
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
GB2474613A (en) * 2008-07-10 2011-04-20 Nodality Inc Methods and apparatus related to management of experiments
US20100014741A1 (en) * 2008-07-10 2010-01-21 Banville Steven C Methods and apparatus related to gate boundaries within a data space
US9183237B2 (en) 2008-07-10 2015-11-10 Nodality, Inc. Methods and apparatus related to gate boundaries within a data space
US20100030719A1 (en) * 2008-07-10 2010-02-04 Covey Todd M Methods and apparatus related to bioinformatics data analysis
JP5692689B2 (en) * 2008-07-11 2015-04-01 日京テクノス株式会社 Method for identifying enzymes related to localization control of biological substances in cells
JP5674664B2 (en) * 2008-09-04 2015-02-25 ベックマン コールター， インコーポレイテッド Evaluation of pankinase activation and signaling pathways
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
US20100209929A1 (en) * 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
US8187885B2 (en) * 2009-05-07 2012-05-29 Nodality, Inc. Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN102625932A (en) * 2009-09-08 2012-08-01 诺达利蒂公司 Analysis of cell networks
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
WO2011037916A1 (en) * 2009-09-28 2011-03-31 Quest Diagnostics Investments Incorporated Method leukemia diagnosis using caspase-3
JP2013520208A (en) * 2010-02-24 2013-06-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ Diagnosis, prognosis and treatment of autoimmune diseases
US10119959B2 (en) 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
CN103501859B (en) 2011-03-02 2017-08-25 博格有限责任公司 Probing analysis and its application based on cell
US20130218474A1 (en) * 2012-01-26 2013-08-22 Nodality, Inc. Benchmarks for Normal Cell Identification
KR20200105524A (en) * 2012-04-02 2020-09-07 버그 엘엘씨 Interrogatory cell-based assays and uses thereof
GB2584364A (en) 2013-03-15 2020-12-02 Abvitro Llc Single cell bar-coding for antibody discovery
US9584119B2 (en) 2013-04-23 2017-02-28 Honeywell International Inc. Triac or bypass circuit and MOSFET power steal combination
GB201309057D0 (en) * 2013-05-20 2013-07-03 Cell Therapy Ltd Method
EP3498288A1 (en) 2013-12-02 2019-06-19 Sirbal Ltd. Herbal combinations for treatment of a skin condition
US10261084B1 (en) 2014-02-19 2019-04-16 Stc.Unm Activated GTPase-based assays and kits for the diagnosis of sepsis and other infections
GB2529695A (en) * 2014-08-29 2016-03-02 Respiratory Clinical Trials Ltd Biomarker assay
US10482385B2 (en) 2014-09-11 2019-11-19 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
SG11201702060VA (en) 2014-09-15 2017-04-27 Abvitro Inc High-throughput nucleotide library sequencing
US9766224B2 (en) 2015-03-25 2017-09-19 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis using secondary ion mass spectrometry
WO2017019651A1 (en) 2015-07-29 2017-02-02 Sirbal Ltd. Herbal combinations for treating psoriasis
US11162945B2 (en) 2016-04-11 2021-11-02 Board Of Regents, The University Of Texas System Methods and compositions for detecting single T cell receptor affinity and sequence
EP3351926A1 (en) * 2017-01-18 2018-07-25 Hifibio Method for analyzing and selecting a specific droplet among a plurality of droplets and associated apparatus
EP4153770A2 (en) 2020-05-22 2023-03-29 Promega Corporation Enhancement of kinase target engagement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968738A (en) * 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
WO2003067210A2 (en) * 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4568649A (en) * 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ES2035317T5 (en) 1987-11-09 1998-03-16 Becton Dickinson Co METHOD FOR ANALYZING HEMATOPOYETIC CELLS IN A SAMPLE.
FR2627566B1 (en) * 1988-02-23 1992-04-10 Valeo TORSION DAMPING DEVICE WITH PERIPHERAL ELASTIC MEANS, ESPECIALLY FOR MOTOR VEHICLES
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4979824A (en) 1989-05-26 1990-12-25 Board Of Trustees Of The Leland Stanford Junior University High sensitivity fluorescent single particle and single molecule detection apparatus and method
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
EP0575319B1 (en) 1991-03-11 1999-11-10 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
US5199576A (en) * 1991-04-05 1993-04-06 University Of Rochester System for flexibly sorting particles
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
US5234816A (en) * 1991-07-12 1993-08-10 Becton, Dickinson And Company Method for the classification and monitoring of leukemias
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
DE69334053T2 (en) * 1992-04-10 2007-01-04 Dana-Farber Cancer Institute, Inc., Boston IMMUNO PROTECTION OF AN ACTIVE STATE-SPECIFIC PHOSPHOPROTEIN
CA2160457A1 (en) 1993-04-19 1994-10-27 Stuart A. Kauffman Random chemistry for the generation of new compounds
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5912137A (en) * 1996-07-16 1999-06-15 The Regents Of The University Of California Assays for protein kinases using fluorescent
US6280967B1 (en) 1996-08-02 2001-08-28 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time of cellular responses
US5804436A (en) 1996-08-02 1998-09-08 Axiom Biotechnologies, Inc. Apparatus and method for real-time measurement of cellular response
US6558916B2 (en) 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
WO1998026277A2 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
EP1057036A1 (en) 1998-02-25 2000-12-06 New York Medical College FLOW CYTOMETRIC DETECTION OF CONFORMATIONS OF pRB IN SINGLE CELLS
US6821740B2 (en) 1998-02-25 2004-11-23 Becton, Dickinson And Company Flow cytometric methods for the concurrent detection of discrete functional conformations of PRB in single cells
US7236888B2 (en) 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
EP1363127A3 (en) 1998-04-17 2004-03-24 Rigel Pharmaceuticals, Inc. Multiparameter facs assays to detect alterations in cellular parameters
WO1999058955A1 (en) * 1998-05-14 1999-11-18 Luminex Corporation Multi-analyte diagnostic system and computer implemented process for same
FR2782730B1 (en) 1998-08-25 2002-05-17 Biocom Sa CELL SEPARATION PROCESS FOR THE ISOLATION OF PATHOGENIC CELLS, PARTICULARLY RARE CANCERES, EQUIPMENT AND REAGENT FOR IMPLEMENTING THE PROCESS AND APPLICATION OF THE PROCESS
US7300753B2 (en) * 1998-09-04 2007-11-27 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) * 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
WO2000048991A1 (en) 1999-02-18 2000-08-24 The Regents Of The University Of California Salicylamide-lanthanide complexes for use as luminescent markers
US6972198B2 (en) * 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
DE60025716T2 (en) * 1999-04-30 2006-10-19 Children's Hospital Medical Center, Cincinnati hemofiltration
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US6673554B1 (en) * 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
US6406869B1 (en) * 1999-10-22 2002-06-18 Pharmacopeia, Inc. Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents
DE60025697D1 (en) * 2000-02-08 2006-04-13 St Microelectronics Srl Booster device
US7912651B2 (en) 2000-03-06 2011-03-22 Bioseek Llc Function homology screening
AU5003001A (en) * 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
JP2003530365A (en) * 2000-04-10 2003-10-14 ザ スクリプス リサーチ インスティチュート Proteomic analysis
US7045286B2 (en) * 2000-07-25 2006-05-16 The Trustees Of The University Of Pennsylvania Methods of detecting molecules expressing selected epitopes via fluorescent dyes
AU2002223950A1 (en) * 2000-09-20 2002-04-02 Qlt Inc. Cancer associated protein kinases and their uses
US6972196B1 (en) * 2000-10-11 2005-12-06 Arch Development Corporation Making surfaces inert by modifying with alkanethiolates
US6972574B2 (en) * 2001-01-31 2005-12-06 Cm Technologies Corporation Method and apparatus for monitoring integrity of wires or electrical cables
US20040170995A1 (en) 2001-02-28 2004-09-02 Phillip Lograsso Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
JP4859276B2 (en) * 2001-03-21 2012-01-25 富士通東芝モバイルコミュニケーションズ株式会社 Communication terminal device and display method
US20020145400A1 (en) * 2001-04-10 2002-10-10 Cashatt Jerry D. Motor load controller for AC induction motors
WO2002087431A1 (en) * 2001-05-01 2002-11-07 Structural Bioinformatics, Inc. Diagnosing inapparent diseases from common clinical tests using bayesian analysis
US20020197658A1 (en) 2001-05-10 2002-12-26 Allen Delaney Cancer associated protein kinase and its use
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7695926B2 (en) * 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
EP1427810B9 (en) * 2001-08-21 2012-04-25 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/scf/pakt status
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2002336504A1 (en) 2001-09-12 2003-03-24 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of Oregon S Method and system for classifying a scenario
WO2003025202A2 (en) 2001-09-19 2003-03-27 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
US7894992B2 (en) * 2001-11-07 2011-02-22 Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
AU2003209340A1 (en) 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
US7183385B2 (en) 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US6972157B2 (en) * 2002-03-26 2005-12-06 Waseda University Magnetic recording medium, production process thereof, and magnetic recording and reproducing apparatus
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
AU2003212162A1 (en) 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein phosphatases and their uses
AU2003223494A1 (en) 2002-04-05 2003-10-27 Cell Signaling Technology, Inc. Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
CA2413475C (en) * 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
CN1665790A (en) * 2002-05-03 2005-09-07 莫莱丘莱尔探针公司 Compositions and methods for detection and isolation of phosphorylated molecules
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
JP3755136B2 (en) * 2002-05-27 2006-03-15 株式会社ロッテ Baked confectionery cup and its manufacturing method
AU2003256453A1 (en) 2002-07-03 2004-01-23 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
US20040126784A1 (en) 2002-07-12 2004-07-01 Rigel Pharmaceuticals, Incorporated Modulators of cellular proliferation
US7537891B2 (en) 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
EP1546103B1 (en) * 2002-10-03 2009-03-18 Vertex Pharmaceuticals Incorporated Piperazine and piperidine derivatives for treatment of neurological diseases
US20040137539A1 (en) 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies
WO2004074452A2 (en) 2003-02-19 2004-09-02 The Regents Of The University Of California Multiplex mapping of protein interactions
US7507548B2 (en) 2003-03-04 2009-03-24 University Of Salamanca Multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry measurements
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
WO2004089972A2 (en) * 2003-04-02 2004-10-21 Merck & Co., Inc. Mass spectrometry data analysis techniques
US20040241636A1 (en) 2003-05-30 2004-12-02 Michnick Stephen William Watson Monitoring gene silencing and annotating gene function in living cells
US7025287B2 (en) * 2003-08-14 2006-04-11 Nelson Irrigation Corporation Shaft seal with grease retainer
US7402399B2 (en) 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
US7326577B2 (en) 2003-10-20 2008-02-05 Esoterix, Inc. Cell fixation and use in phospho-proteome screening
JP4879477B2 (en) * 2003-12-08 2012-02-22 インベンテイオ・アクテイエンゲゼルシヤフト Elevator door drive device
EP1792177B1 (en) 2004-08-12 2010-11-17 Transform Pharmaceuticals, Inc. Methods for identifiying conditions affecting a cell state
US20060040338A1 (en) 2004-08-18 2006-02-23 Odyssey Thera, Inc. Pharmacological profiling of drugs with cell-based assays
US7803523B2 (en) * 2004-08-27 2010-09-28 University Health Network Whole blood preparation for cytometric analysis of cell signaling pathways
WO2006069203A2 (en) * 2004-12-22 2006-06-29 California Institute Of Technology Methods for proteomic profiling using non-natural amino acids
EP1842147A2 (en) * 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Method for modeling cell signaling systems by means of bayesian networks
WO2006096704A2 (en) * 2005-03-07 2006-09-14 Invitrogen Corporation Isotopically-labeled proteome standards
DK1889065T3 (en) * 2005-05-18 2013-09-02 Xoma Technology Ltd METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES WITH AN AUTO-IMMUNE AND / OR INFLAMMATION COMPONENT
JP2007046697A (en) 2005-08-10 2007-02-22 Fujikin Inc Jointed fluid controller
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
WO2007117423A2 (en) * 2006-03-31 2007-10-18 Cira Discovery Sciences, Inc. Method and apparatus for representing multidimensional data
EP2179037A4 (en) * 2007-08-21 2010-12-22 Nodality Inc Methods for diagnosis, prognosis and methods of treatment
GB2474146B (en) * 2008-04-29 2013-04-10 Nodality Inc Methods of determining the health status of an individual
US20090269800A1 (en) * 2008-04-29 2009-10-29 Todd Covey Device and method for processing cell samples
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
GB2474613A (en) * 2008-07-10 2011-04-20 Nodality Inc Methods and apparatus related to management of experiments
US20100014741A1 (en) * 2008-07-10 2010-01-21 Banville Steven C Methods and apparatus related to gate boundaries within a data space
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US20100030719A1 (en) * 2008-07-10 2010-02-04 Covey Todd M Methods and apparatus related to bioinformatics data analysis
US8399206B2 (en) * 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
JP5674664B2 (en) 2008-09-04 2015-02-25 ベックマン コールター， インコーポレイテッド Evaluation of pankinase activation and signaling pathways
WO2010045651A1 (en) 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
US9034257B2 (en) * 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US20100209929A1 (en) * 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
US8187885B2 (en) * 2009-05-07 2012-05-29 Nodality, Inc. Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
CN102625932A (en) 2009-09-08 2012-08-01 诺达利蒂公司 Analysis of cell networks
JP2013520208A (en) 2010-02-24 2013-06-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ Diagnosis, prognosis and treatment of autoimmune diseases
US20110262468A1 (en) * 2010-04-23 2011-10-27 Nodality, Inc. Method for Monitoring Vaccine Response Using Single Cell Network Profiling
AU2011264714A1 (en) * 2010-06-09 2012-12-20 Nodality, Inc. Pathways characterization of cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968738A (en) * 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
WO2003067210A2 (en) * 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IRISH J.M. ET AL.: "Single cell profiling of potentiated phospho-protein networks in cancer cells.", CELL, vol. 118, 23 July 2004 (2004-07-23), pages 217 - 228, XP002386692 *
KRUTZIK P.O. ET AL.: "Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications.", CLIN. IMMUNOL., vol. 110, March 2004 (2004-03-01), pages 206 - 221, XP002386691 *
PEREZ O.D. ET AL.: "LFA-1 signaling through p44/42 is coupled to perforin degranulation in CD56+CD8+ natural killer cells.", BLOOD, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1083 - 1093, XP002386693 *
PEREZ O.D. ET AL.: "Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry.", NATURE BIOTECH., vol. 20, February 2002 (2002-02-01), pages 155 - 162, XP002386690 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815527B2 (en) 2001-07-10 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US9115384B2 (en) 2001-07-10 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US8865420B2 (en) 2004-07-21 2014-10-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US9182385B2 (en) 2007-08-21 2015-11-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8273544B2 (en) 2008-07-10 2012-09-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8778620B2 (en) 2008-07-10 2014-07-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9500655B2 (en) 2008-07-10 2016-11-22 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9034257B2 (en) 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US8309306B2 (en) 2008-11-12 2012-11-13 Nodality, Inc. Detection composition

Also Published As

Publication number Publication date
CN101023353B (en) 2015-08-12
US20110207149A1 (en) 2011-08-25
US20080254489A1 (en) 2008-10-16
US8309316B2 (en) 2012-11-13
US20090081699A1 (en) 2009-03-26
US7939278B2 (en) 2011-05-10
US20110269634A1 (en) 2011-11-03
JP2014055964A (en) 2014-03-27
JP2015072286A (en) 2015-04-16
WO2006012507A2 (en) 2006-02-02
US20090068681A1 (en) 2009-03-12
US7393656B2 (en) 2008-07-01
US8394599B2 (en) 2013-03-12
US20050112700A1 (en) 2005-05-26
US20120070849A1 (en) 2012-03-22
EP1771728A2 (en) 2007-04-11
US8206939B2 (en) 2012-06-26
EP2302379A1 (en) 2011-03-30
US8865420B2 (en) 2014-10-21
JP2008507286A (en) 2008-03-13
US20080182262A1 (en) 2008-07-31
US20110201018A1 (en) 2011-08-18
US20100221750A1 (en) 2010-09-02
CN101023353A (en) 2007-08-22

Similar Documents

Publication Publication Date Title
WO2006012507A3 (en) Methods and compositions for risk stratification
WO2006055689A3 (en) Protein scaffolds and uses thereof
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2006060646A3 (en) Cell microarray for profiling of cellular phenotypes and gene function
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2003048300A3 (en) Methods of identifying cellular target molecules
AU2001268449A1 (en) Toxicity typing using liver stem cells
WO2002077604A3 (en) Labeled cells for use as an internal functional control in rare cell detection assays
WO2005076887A3 (en) Methods and systems for sampling, screening, and diagnosis
WO2008088857A3 (en) Methods and compositions for detecting receptor-ligand interactions in single cells
WO2006108087A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2007010379A3 (en) Calorimetric assessment of microorganisms and use thereof
WO2007079229A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2006048262A3 (en) Classification of acute myeloid leukemia
WO2007118242A3 (en) Identification of a constitutively resistant cancer stem cell
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2002079491A3 (en) Method for correlating gene expression profiles with protein expression profiles
WO2006055338A3 (en) Methods and systems for identifying and isolating stem cells and for observing mitochondrial structure and distribution in living cells
WO2005121365A3 (en) Identifying chromosomal abnormalities in cells obtained from follicular fluid
WO2004062487A3 (en) Methods of detecting gene expression in normal and cancerous cells
WO2006127040A3 (en) Protein scaffolds and uses therof
WO2005074522A3 (en) Detection of ruminant dna via pcr
WO2006048266A3 (en) Gene expression profiling of leukemias with mll gene rearrangements
WO2006060591A3 (en) Determination of cell viability and phenotype
WO2005089509A3 (en) High throughput assay systems and methods for identifying agents that alter expression of cellular proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007522799

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005775258

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580031373.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005775258

Country of ref document: EP